Article
Biochemistry & Molecular Biology
Jiawei Lv, Yuan Wei, Jian-Hua Yin, Yu-Pei Chen, Guan-Qun Zhou, Chen Wei, Xiao-Yu Liang, Yuan Zhang, Cui-Juan Zhang, Shi-Wei He, Qing-Mei He, Zhuo-Li Huang, Jia-Li Guan, Jia-Yi Shen, Xiao-Min Li, Jun-Yan Li, Wen-Fei Li, Ling-Long Tang, Yan-Ping Mao, Rui Guo, Rui Sun, Yu-Hui Zheng, Wen-Wen Zhou, Ke-Xu Xiong, Si-Qi Wang, Xin Jin, Na Liu, Gui-Bo Li, Dong-Ming Kuang, Ying Sun, Jun Ma
Summary: By using single-cell RNA sequencing and T cell and B cell receptor sequencing, this study reveals that Gemcitabine plus cisplatin (GP) chemotherapy activates an innate-like B cell (ILB)-dominant antitumor immune response, which enhances cytotoxic T cells and improves the treatment outcome for patients with nasopharyngeal carcinoma (NPC). ILB frequency serves as a potential biomarker for predicting favorable outcomes in patients receiving GP-based treatment and immunotherapy combined treatment.
Article
Medicine, Research & Experimental
Qian Chen, Shan Li
Summary: This study compares the reduction in tumor volume after induction chemotherapy with gemcitabine plus cisplatin and docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma. It was found that gemcitabine plus cisplatin achieved a greater reduction in gross tumor volume of the nasopharynx and had advantages in subsequent chemoradiotherapy dose planning parameters.
Article
Oncology
Xiao-Min Li, Xiao-Min Zhang, Jun-Yan Li, Ning Jiang, Lei Chen, Ling-Long Tang, Yan-Ping Mao, Wen-Fei Li, Guan-Qun Zhou, Ying-Qin Li, Na Liu, Yuan Zhang, Jun Ma
Summary: The study found that in nasopharyngeal carcinoma patients undergoing gemcitabine and cisplatin (GP) induction chemotherapy, immunosuppressive cells decreased significantly while T cells, B cells, and pro-inflammatory cytokines increased significantly. The cytotoxic activity and proliferative capacity of T cells were not weakened by GP chemotherapy. These results provide a solid basis for combining GP with immunotherapy in the treatment of nasopharyngeal carcinoma.
Article
Oncology
Maen Abdelrahim, Abdullah Esmail, Jiaqiong Xu, Godsfavour Umoru, Hadeel Al-Rawi, Ashish Saharia, Ala Abudayyeh, David Victor, Robert McMillan, Sudha Kodali, Rafik M. Ghobrial
Summary: This study investigates the potential efficacy of Gemcitabine plus Cisplatin as a neo-adjuvant treatment for cholangiocarcinoma patients prior to liver transplantation. The results suggest improved overall survival outcomes with Gemcitabine plus Cisplatin compared to non-Gemcitabine/Cisplatin regimens in these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
M. S. van der Heijden, G. Sonpavde, T. Powles, A. Necchi, M. Burotto, M. Schenker, J. P. Sade, A. Bamias, P. Beuzeboc, J. Bedke, J. Oldenburg, G. Chatta, Y. Urun, D. Ye, Z. He, B. P. Valderrama, J. H. Ku, Y. Tomita, J. Filian, L. Wang, D. Purcea, M. Y. Patel, F. Nasroulah, M. D. Galsky
Summary: In patients with previously untreated advanced urothelial carcinoma, combination therapy with nivolumab plus gemcitabine-cisplatin resulted in significantly better outcomes compared to gemcitabine-cisplatin alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Margherita Rimini, Lorenzo Fornaro, Sara Lonardi, Monica Niger, Daniele Lavacchi, Tiziana Pressiani, Jessica Lucchetti, Guido Giordano, Andrea Pretta, Emiliano Tamburini, Chiara Pirrone, Ilario Giovanni Rapposelli, Anna Diana, Erika Martinelli, Ingrid Garajova, Francesca Simionato, Marta Schirripa, Vincenzo Formica, Caterina Vivaldi, Enrico Caliman, Mario Domenico Rizzato, Valentina Zanuso, Federico Nichetti, Lorenzo Angotti, Matteo Landriscina, Mario Scartozzi, Matteo Ramundo, Alessandro Pastorino, Bruno Daniele, Noemi Cornara, Mara Persano, Eleonora Gusmaroli, Riccardo Cerantola, Francesca Salani, Francesca Ratti, Luca Aldrighetti, Stefano Cascinu, Lorenza Rimassa, Lorenzo Antonuzzo, Andrea Casadei-Gardini
Summary: This study investigated the efficacy and safety of the combination of durvalumab, gemcitabine, and cisplatin in patients with advanced biliary tract cancer. The results showed that the median progression-free survival was 8.9 months, and the median overall survival was 12.9 months. The overall response rate was 34.5% and the disease control rate was 87.6%. Adverse events were mainly mild, with a small percentage of immune-mediated adverse events observed.
LIVER INTERNATIONAL
(2023)
Article
Oncology
Shaodong Hong, Yaxiong Zhang, Gengsheng Yu, Peijian Peng, Jiewen Peng, Jun Jia, Xuan Wu, Yan Huang, Yunpeng Yang, Qing Lin, Xuping Xi, Mingjun Xu, Dongping Chen, Xiaojun Lu, Rensheng Wang, Xiaolong Cao, Xiaozhong Chen, Zhixiong Lin, Jianping Xiong, Qin Lin, Conghua Xie, Zhihua Li, Jianji Pan, Jingao Li, Shixiu Wu, Yingni Lian, Quanlie Yang, Chong Zhao, Wenfeng Fang, Li Zhang
Summary: The study found that among patients with previously untreated advanced nasopharyngeal carcinoma, those who received GP had longer overall survival compared to those who received FP. Gemcitabine plus cisplatin may be a preferred frontline option for these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Otorhinolaryngology
Zhen-Chong Yang, Chao-Chao Du, Ting Liu, Li-Ting Liu, Qiu-Yan Chen, Shan-Shan Guo, Hai-Qiang Mai
Summary: The study found significant differences in survival outcomes between patients treated with GP PCT within 2 years and 2 years after GP IC, as well as those receiving non-GP PCT.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Article
Otorhinolaryngology
Qian Chen, Liangfang Shen, Shan Li
Summary: This study retrospectively evaluated the tumor volume reduction in nasopharyngeal carcinoma patients who received gemcitabine plus cisplatin induction chemotherapy and constructed prediction models for tumor volume reduction. The results showed that the volume reduction was associated with several factors. By building the nomogram models, the possibility of tumor volume reduction can be predicted accurately.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2023)
Article
Oncology
Hongsik Kim, Byong Chang Jeong, Joohyun Hong, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Wan Song, Hyun Hwan Sung, Jung Yong Hong, Se Hoon Park
Summary: The aim of this study was to test the activity and safety of neoadjuvant nivolumab plus gemcitabine/cisplatin (N+GC) in patients with muscle-invasive bladder urothelial carcinoma (MIBC). The results showed that N+GC could effectively slow down the progression of the disease and produce positive pathological responses in patients.
CANCER RESEARCH AND TREATMENT
(2023)
Review
Immunology
Wei Zhang, Chu Luo, Zun-Yi Zhang, Bi-Xiang Zhang, Xiao-Ping Chen
Summary: The combination of lenvatinib and pembrolizumab with GP chemotherapy achieved significant tumor reduction and decreased tumor marker levels in a patient with unresectable ICC. The patient underwent successful liver resection and has survived 15 months without recurrence or metastasis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Erika Fiorino, Alessandra Merlini, Lorenzo D'Ambrosio, Ilaria Cerviere, Enrico Berrino, Caterina Marchio, Lidia Giraudo, Marco Basirico, Annamaria Massa, Chiara Donini, Valeria Leuci, Ramona Rotolo, Federica Galvagno, Letizia Vitali, Alessia Proment, Soldano Ferrone, Alberto Pisacane, Ymera Pignochino, Massimo Aglietta, Giovanni Grignani, Giulia Mesiano, Dario Sangiolo
Summary: This study investigates the immunotherapy efficacy on imatinib and sunitinib-resistant wild-type gastrointestinal stromal tumors (wtGIST) using a patient-derived preclinical model. The results show that cytokine-induced killer lymphocytes (CIK) can kill resistant wtGIST cells, and interferons (IFN) have anti-tumor effects on certain resistant wtGIST cells. These findings support the exploration of CIK immunotherapy in clinical studies and the reevaluation of IFN within this challenging setting.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Shi-Wei He, Yuan Zhang, Lei Chen, Wei-Jie Luo, Xiao-Min Li, Yang Chen, Sheng-Yan Huang, Qing-Mei He, Xiao-Jing Yang, Ying-Qin Li, Na Liu, Yin Zhao, Jun Ma
Summary: The combination of gemcitabine and cisplatin significantly inhibits NPC cell proliferation and tumor growth by inducing cell cycle arrest, cell apoptosis, and DNA damage response, revealing the mechanisms of improving locoregionally advanced NPC with combined GEM and DDP induction chemotherapy.
Article
Oncology
Lei Zhang, Yan Wang, Xin Li, Ling Li, Xinhua Wang, Zhenchang Sun, Jingjing Wu, Xiaorui Fu, Xudong Zhang, Hui Yu, Guannan Wang, Yu Chang, Jiaqin Yan, Zhiyuan Zhou, Xiaolong Wu, Feifei Nan, Wencai Li, Mingzhi Zhang
Summary: This study compared the efficacy and safety of RT and DDGP combined with RT in newly diagnosed stage I-II NKTL patients. DDGP combined with RT showed superior CRR, ORR, 5-year PFS, and OS rates compared to RT alone, but also had more side effects.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Makito Miyake, Yuki Oda, Takuya Owari, Kota Iida, Sayuri Ohnishi, Tomomi Fujii, Nobutaka Nishimura, Tatsuki Miyamoto, Takuto Shimizu, Kenta Ohnishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Kazumasa Torimoto, Nobumichi Tanaka, Kiyohide Fujimoto
Summary: This study investigated the effects of chemotherapy drugs on the gut microbiome and explored the potential benefits of oral supplementation of probiotics in enhancing the anti-tumor immune response. The results demonstrated that probiotics could alter the gut microbiome and improve the anti-tumor effects.